» Articles » PMID: 23804264

Gut Microbiota and Type 1 Diabetes

Overview
Journal Rev Diabet Stud
Specialty Endocrinology
Date 2013 Jun 28
PMID 23804264
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The gut immune system has a key role in the development of autoimmune diabetes, and factors that control the gut immune system are also regulators of beta-cell autoimmunity. Gut microbiota modulate the function of the gut immune system by their effect on the innate immune system, such as the intestinal epithelial cells and dendritic cells, and on the adaptive immune system, in particular intestinal T cells. Due to the immunological link between gut and pancreas, e.g. the shared lymphocyte homing receptors, the immunological changes in the gut are reflected in the pancreas. According to animal studies, changes in gut microbiota alter the development of autoimmune diabetes. This has been demonstrated by antibiotics that induce changes in the gut microbiota. Furthermore, gut-colonizing microbes may modify the incidence of autoimmune diabetes in animal models. Deficient toll-like receptor (TLR) signaling, mediating microbial stimulus in immune cells, prevents autoimmune diabetes, which appears to be dependent on alterations in the intestinal microbiota. Although few studies have been conducted in humans, recent studies suggest that the abundance of Bacteroides and lack of butyrate-producing bacteria in fecal microbiota are associated with beta-cell autoimmunity and type 1 diabetes. It is possible that altered gut microbiota are associated with immunological aberrancies in type 1 diabetes. The changes in gut microbiota could lead to alterations in the gut immune system, such as increased gut permeability, small intestinal inflammation, and impaired tolerance to food antigens, all of which are observed in type 1 diabetes. Poor fitness of gut microbiota could explain why children who develop type 1 diabetes are prone to enterovirus infections, and do not develop tolerance to cow milk antigens. These candidate risk factors of type 1 diabetes may imply an increased risk of type 1 diabetes due to the presence of gut microbiota that do not support health. Despite the complex interaction of microbiota, host, environment, and disease mechanisms, gut microbiota are promising novel targets in the prevention of type 1 diabetes.

Citing Articles

Diabetes and gut microbiome.

Fliegerova K, Mahayri T, Sechovcova H, Mekadim C, Mrazek J, Jarosikova R Front Microbiol. 2025; 15():1451054.

PMID: 39839113 PMC: 11747157. DOI: 10.3389/fmicb.2024.1451054.


Probiotic treatment with viable α-galactosylceramide-producing Bacteroides fragilis reduces diabetes incidence in female nonobese diabetic mice.

Hansen C, Jozipovic D, Zachariassen L, Nielsen D, Hansen A, Buschard K J Diabetes. 2024; 16(8):e13593.

PMID: 39136533 PMC: 11320754. DOI: 10.1111/1753-0407.13593.


Supplementation of High-Strength Oral Probiotics Improves Immune Regulation and Preserves Beta Cells among Children with New-Onset Type 1 Diabetes Mellitus: A Randomised, Double-Blind Placebo Control Trial.

Lokesh M, Kumar R, Jacob N, Sachdeva N, Rawat A, Yadav J Indian J Pediatr. 2024; 92(3):277-283.

PMID: 38557820 DOI: 10.1007/s12098-024-05074-5.


Metabolic Syndrome: A Narrative Review from the Oxidative Stress to the Management of Related Diseases.

Martemucci G, Fracchiolla G, Muraglia M, Tardugno R, Dibenedetto R, DAlessandro A Antioxidants (Basel). 2023; 12(12).

PMID: 38136211 PMC: 10740837. DOI: 10.3390/antiox12122091.


Gut microbiome and blood glucose control in type 1 diabetes: a systematic review.

Abuqwider J, Corrado A, Scida G, Lupoli R, Costabile G, Mauriello G Front Endocrinol (Lausanne). 2023; 14:1265696.

PMID: 38034007 PMC: 10684760. DOI: 10.3389/fendo.2023.1265696.


References
1.
de Goffau M, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen T . Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013; 62(4):1238-44. PMC: 3609581. DOI: 10.2337/db12-0526. View

2.
Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E . Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes. 2003; 52(9):2287-95. DOI: 10.2337/diabetes.52.9.2287. View

3.
Lochner M, Berard M, Sawa S, Hauer S, Gaboriau-Routhiau V, Fernandez T . Restricted microbiota and absence of cognate TCR antigen leads to an unbalanced generation of Th17 cells. J Immunol. 2010; 186(3):1531-7. DOI: 10.4049/jimmunol.1001723. View

4.
Brown C, Davis-Richardson A, Giongo A, Gano K, Crabb D, Mukherjee N . Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011; 6(10):e25792. PMC: 3197175. DOI: 10.1371/journal.pone.0025792. View

5.
Turnbaugh P, Hamady M, Yatsunenko T, Cantarel B, Duncan A, Ley R . A core gut microbiome in obese and lean twins. Nature. 2008; 457(7228):480-4. PMC: 2677729. DOI: 10.1038/nature07540. View